Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer
Zhang, Yaqin , Mehta, Amit, Boufraqech, Myriem , Tian, Ze , Yu, Zhiya , Boxer, Matthew B., Kiefer, Jeffrey , Copland, John A. , Smallridge, Robert C., Li, Zhuyin, Kebebew, Electron , Zhang, Lisa M. , Davis, Sean , Wang, Jing , Shen, Min

Mayo Clinic

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 11 | Pages: 9073-9085

10.18632/oncotarget.3268 | PMID 25940539 Get It

Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer
Xia, Shu , Du, Meijun , Nandy, Debashis, Yuan, Tiezheng , Guo, Yongchen, Tschannen, Michael, See, William A., Kilari, Deepak , Wang, Xuexia , Hovey, Raymond , Huang, Chiang‐Ching , Kohli, Manish , Dittmar, Rachel L. , Lee, Adam, Wang, Yuan , Worthey, Elizabeth A. , Jacob, Howard J. , Wang, Liang

Mayo Clinic

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 18 | Pages: 16411-16421

10.18632/oncotarget.3845 | PMID 25915538 Get It

Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals
Reitz, Christiane , Cheng, Rong , Jun, Gyungah , Sato, Christine , Rajbhandary, Ruchita, Wang, Li San, Lin, Chiao‐Feng , Larson, Eric B., Graff‐Radford, Neill R. , Evans, Denis A., Jager, Philip L. De , Crane, Paul K. , Buxbaum, Joseph D. , Murrell, Jill R. , Raj, Towfique , Ertekin‐Taner, Nilüfer , Logue, Mark, Baldwin, Clinton T., Green, Robert C. , Barnes, Lisa L. , Cantwell, Laura B., Fallin, M. Daniele , Go, Rodney C.P., Griffith, Patrick , Obisesan, Thomas O. , Bennett, David A. , Hendrie, Hugh C. , Hall, Kathleen, Byrd, Goldie S. , Kukull, Walter A. , Foroud, Tatiana M., Haines, Jonathan L. , Farrer, Lindsay A. , Pericak‐Vance, Margaret A. , Schellenberg, Gerard D. , Mayeux, Richard , Morris, John C. , Leverenz, James B. , DeKosky, Steven T. , Håkonarson, Håkon , Jarvik, Gail P. , Albin, Roger L. , Lyketsos, Constantine G. , Jicha, Gregory A. , Demirci, F. Yesim , Burke, James R. , Cao, Chuanhai , Carroll, Steven L. , Cribbs, David H. , Mack, Wendy J. , Sonnen, Joshua A. , Bennett, David A. , Ghani, Mahdi , Vardarajan, Badri Narayan , Naj, Adam Christian , Valladares, Otto , Manly, Jennifer J. , Lunetta, Kathryn L. , Kamboh, M. Ilyas , López, Oscar L. , Goate, Alison , Lee, Joseph H. , George‐Hyslop, Peter St , Rogaeva, Ekaterina A. , Hakonarson, Hakon , Leverenz, James B , Jarvik, Gail P , Morris, John C , Jicha, Gregory A , Sonnen, Joshua , Barnes, Lisa L

Mayo Clinic

JAMA Neurology | September 14, 2015 | Volume: 72 | Issue: 11 | Pages: 1313

10.1001/jamaneurol.2015.1700 | PMID 26366463 Get It

Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk
Long, Jirong , Zeng, Chenjie , Michailidou, Kyriaki , Ghoussaini, Maya , Bolla, Manjeet K. , Wang, Qin, Shu, Xiao-Ou, Beesley, Jonathan, Kar, Siddhartha , Andrulis, Irene L. , Beckmann, Matthias W. , Beeghly‐Fadiel, Alicia, Benı́tez, Javier , Blot, William J. , Bogdanova, Natalia , Bojesen, Stig E. , Brauch, Hiltrud , Brenner, Hermann , Brinton, Louise A. , Brüning, Thomas , Burwinkel, Barbara , Cai, Hui , Canisius, Sander , Chang‐Claude, Jenny , Choi, Ji‐Yeob , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Darabi, Hatef, Devilee, Peter , Droit, Arnaud , Dörk, Thilo , Fasching, Peter A. , Fletcher, Olivia , Flyger, Henrik, Fostira, Florentia, Gaborieau, Valérie , García‐Closas, Montserrat , Giles, Graham G. , Grip, Mervi, Guénel, Pascal , Haiman, Christopher A., Hamann, Ute , Hartman, Mikael , Hollestelle, Antoinette , Hopper, John L. , Hsiung, Chia-Ni, Jakubowska, Anna , Johnson, Nichola , Kabisch, Maria, Kang, Daehee , Khan, Sofia , Knight, Julia A. , Kosma, Veli-Matti, Lambrechts, Diether , Li, Jingmei , Lindblom, Annika , Lubiński, Jan , Mannermaa, Arto, Manoukian, Siranoush , Margolin, Sara , Matsuo, Keitaro , McLean, Catriona , Meindl, Alfons , Muir, Kenneth , Orr, Nick , Peterlongo, Paolo , Putti, Thomas Choudary , Sangrajrang, Suleeporn , Sawyer, Elinor J. , Schmidt, Marjanka K. , Schmutzler, Rita K., Shrubsole, Martha J. , Southey, Melissa C. , Swerdlow, Anthony J. , Teo, Soo‐Hwang , Thienpont, Bernard , Tollenaar, Robert A.E.M., Tomlinson, Ian , Truong, Thérèse , Tseng, Chiu-Chen, Ouweland, Ans van den, Wen, Wanqing , Winqvist, Robert , Wu, Anna H. , Yip, Cheng Har , Zamora, M. Pilar , Zheng, Ying , Simard, Jacques , Chenevix‐Trench, Georgia , Investigators, on behalf of kConFab, Dunning, Alison M. , Easton, Douglas F. , Zheng, Wei , Wang, Sophia , Radice, Paolo , Webb, Penelope M. , Whiteman, David C. , Pepłońska, Beata , Durocher, Francine , Heikkinen, Tuomas , Balasubramanian, Sabapathy P. , DeFazio, Anna , Peissel, Bernard , Zaffaroni, Daniela , Hillemanns, Peter , Kerin, Michael J. , Pylkäs, Katri , Thorne, Heather , Cai, Hui , Laurent‐Puig, Pierre , Lambrechts, Diether , Taib, Nur Aishah Mohd , Colleran, Gabrielle , Fazio, Anna de , Guo, Xingyi , Wang, Qin, Milne, Roger L. , Cai, Qiuyin , Anton‐Culver, Hoda , Arndt, Volker , Beeghly‐Fadiel, Alicia , Broeks, Annegien , Couch, Fergus J. , Czene, Kamila , Ito, Hidemi , Marchand, Loı̈c Le , Lophatananon, Artitaya , Mannermaa, Arto, Marmé, Frederik , Meindl, Alfons , Neuhausen, Susan L. , Nevanlinna, Heli , Nord, Silje , Olson, Janet E. , Rudolph, Anja , Shen, Chen‐Yang , Shi, Jiajun , Toland, Amanda Ewart , Hall, Per N , Pharoah, Paul D.P. , Investigators, on behalf of kConFab, Dörk, Thilo , Lambrechts, Diether , Giles, Graham G , Peterlongo, Paolo , Teo, Soo H , Webb, Penelope M , Hillemanns, Peter , Shrubsole, Martha J , Swerdlow, Anthony J , Radice, Paolo , Southey, Melissa C , Muir, Kenneth , Matsuo, Keitaro , Dunning, Alison M , Jakubowska, Anna , Lambrechts, Diether , Brenner, Hermann , Cox, Angela , Guénel, Pascal , Hartman, Mikael , Li, Jingmei , García-Closas, Montserrat , Schmidt, Marjanka K , Michailidou, Kyriaki , Bogdanova, Natalia V , Benitez, Javier , Simard, Jacques , Chenevix-Trench, Georgia , Zheng, Wei , Wang, Sophia S , Whiteman, David C , Kar, Siddhartha , Pylkäs, Katri , Laurent-Puig, Pierre , Devilee, Peter , Manoukian, Siranoush , Lubinski, Jan , Fletcher, Olivia , Bojesen, Stig E , Truong, Therese , Mclean, Catriona , Brauch, Hiltrud , Lindblom, Annika , Mohd Taib, Nur Aishah , Sawyer, Elinor J , Orr, Nick , Kang, Daehee , Droit, Arnaud

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 10, 2015 | Volume: 24 | Issue: 11 | Pages: 1680-1691

10.1158/1055-9965.epi-15-0363 | PMID 26354892 Get It

Abstract Background: A recent association study identified a common variant (rs9790517) at 4q24 to be associated with breast cancer risk. Independent association signals and potential functional variants in this locus have not been explored. Methods: We conducted a fine-mapping analysis in 55,540 breast cancer cases and 51,168 controls from the Breast Cancer Association Consortium. Results: Conditional analyses identified two independent association signals among women of European ancestry, represented by rs9790517 [conditional P = 2.51 × 10−4; OR, 1.04; 95% confidence interval (CI), 1.02–1.07] and rs77928427 (P = 1.86 × 10−4; OR, 1.04; 95% CI, 1.02–1.07). Functional annotation using data from the Encyclopedia of DNA Elements (ENCODE) project revealed two putative functional variants, rs62331150 and rs73838678 in linkage disequilibrium (LD) with rs9790517 (r2 ≥ 0.90) residing in the active promoter or enhancer, respectively, of the nearest gene, TET2. Both variants are located in DNase I hypersensitivity and transcription factor–binding sites. Using data from both The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), we showed that rs62331150 was associated with level of expression of TET2 in breast normal and tumor tissue. Conclusion: Our study identified two independent association signals at 4q24 in relation to breast cancer risk and suggested that observed association in this locus may be mediated through the regulation of TET2. Impact: Fine-mapping study with large sample size warranted for identification of independent loci for breast cancer risk. Cancer Epidemiol Biomarkers Prev; 24(11); 1680–91. ©2015 AACR.
Paraspinal neurofibromas and hypertrophic neuropathy in Noonan syndrome with multiple lentigines
Conboy, Erin , Dhamija, Radhika , Wang, Margaret , Xie, Jing , Dyck, P. James B. , Bridges, Alina G. , Spinner, Robert J. , Clayton, Amy C., Watson, Robert E. , Messiaen, Ludwine , Babovic‐Vuksanovic, Dusica , Dyck, P James, Dhamija, Radhika

Mayo Clinic

Journal of Medical Genetics | September 2, 2015 | Volume: 53 | Issue: 2 | Pages: 123-126

10.1136/jmedgenet-2015-103177 | PMID 26337637 Get It

Background Noonan syndrome with multiple lentigines (NSML), formerly known as LEOPARD syndrome, is an autosomal-dominant disorder characterised by lentigines, EKG abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, growth retardation and deafness. There is significant clinical overlap between NSML and other disorders that result from dysregulated rat sarcoma/mitogen-activated protein kinase pathway (RASopathies). Except for neurofibromatosis type 1, other RASopathies are not known to be typically associated with neurogenic tumours. Methods and results We evaluated patients from three families with pigmentary skin lesions, progressive neuropathy, enlarged nerves, massive burden of paraspinal tumours (neurofibroma was confirmed in one patient) and a clinical diagnosis of NSML. All patients had a mutation in the protein tyrosine phosphatase catalytic domain of the PTPN11 gene; two unrelated patients had the p.Thr468Met mutation, while the family consisting of two affected individuals harboured the p.Thr279Cys mutation. Molecular analysis performed on hypertrophic nerve tissue did not disclose a second somatic hit in NF1, PTPN11, NF2 or SMARCB1 genes. Conclusions Neurogenic tumours and hypertrophic neuropathy are unusual complications of NSML and may be an under-recognised manifestation that would warrant surveillance. Our observation may also have implications for other disorders caused by RAS-pathway dysregulation.
Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium
Laurent, Louise C. , Abdel‐Mageed, Asim B. , Adelson, P. David , Arango, Jorge , Balaj, Leonora , Breakefield, Xandra O., Carlson, Elizabeth, Majem, Blanca , Chen, Clark C. , Cocucci, Emanuele , Danielson, Kirsty , Courtright, Amanda, Das, Saumya , Enderle, Daniel , Ezrin, Alan M., Galas, David J. , Gandhi, Roopali, Huentelman, Matthew J. , Keuren‐Jensen, Kendall Van , Kalani, Yashar, Kim, Yong , Krichevsky, Anna M. , Lai, Charles Pin‐Kuang , Lal‐Nag, Madhu , Laurent, Clara D., Leonardo, Trevor R. , Malenica, Ivana , Mondal, Debasis , Nejad, Parham, Raffaı̈, Robert L. , Rubio, Renee, Skog, Johan , Spetzler, Robert, Sun, Jie , Tanrıverdi, Kahraman , Vickers, Kasey C. , Wang, Yaoyu, Weiner, Howard L. , Yeri, Ashish, Gould, Stephen J. , Breakefield, Xandra O. , Courtright-Lim, Amanda , Yan, Irene K. , Laurent, Louise C , Carter, Bob S. , Elmageed, Zakaria Y. Abd , Ferrer, Marc , Freedman, Jane E. , Li, Feng , Patel, Tushar , Wang, Liang , Wang, Yaoyu, Wei, Zhiyun , Wong, David T.

Mayo Clinic

Journal of Extracellular Vesicles | August 28, 2015 | Volume: 4 | Issue: 1 | Pages: No page available

10.3402/jev.v4.26533 | PMID 26320937 Get It

Extracellular RNAs (exRNAs) have been identified in all tested biofluids and have been associated with a variety of extracellular vesicles, ribonucleoprotein complexes and lipoprotein complexes. Much of the interest in exRNAs lies in the fact that they may serve as signalling molecules between cells, their potential to serve as biomarkers for prediction and diagnosis of disease and the possibility that exRNAs or the extracellular particles that carry them might be used for therapeutic purposes. Among the most significant bottlenecks to progress in this field is the lack of robust and standardized methods for collection and processing of biofluids, separation of different types of exRNA‐containing particles and isolation and analysis of exRNAs. The Sample and Assay Standards Working Group of the Extracellular RNA Communication Consortium is a group of laboratories funded by the U.S. National Institutes of Health to develop such methods. In our first joint endeavour, we held a series of conference calls and in‐person meetings to survey the methods used among our members, placed them in the context of the current literature and used our findings to identify areas in which the identification of robust methodologies would promote rapid advancements in the exRNA field.
MicroRNA‐200 promotes lung cancer cell growth through FOG2‐independent AKT activation
Guo, Lixia , Lü, Qiang , Zhang, Ting, Yang, Yanan , Wang, Jingyu , Yang, Ping , Zhang, Ting, Yang, Yanan

Mayo Clinic

IUBMB Life | August 28, 2015 | Volume: 67 | Issue: 9 | Pages: 720-725

10.1002/iub.1412 | PMID 26314828 Get It

AbstractMicroRNA‐200 (miR‐200) has emerged as a regulator of the PI3K/AKT pathway and cancer cell growth. It was reported that miR‐200 can activate PI3K/AKT by targeting FOG2 (friend of GATA 2), which directly binds to the p85α regulatory subunit of PI3K. We found that miR‐200 was elevated in early stage lung adenocarcinomas when compared with normal lung tissues, and the expression of miR‐200 promoted the tumor spheroid growth of lung adenocarcinoma cells. We show that AKT activation was essential for such oncogenic action of miR‐200. However, depletion of FOG2 had little effect on AKT activation. By performing a reverse‐phase protein array, we found that miR‐200 not only activated AKT but also concomitantly inactivated S6K and increased IRS‐1, an S6K substrate that is increased on S6K inactivation. Depletion of IRS‐1 partially inhibited the miR‐200‐dependent AKT activation. Taken together, our results suggest that miR‐200 may activate AKT in lung adenocarcinoma cells through a FOG2‐independent mechanism involving IRS‐1. Our findings also provide evidence that increased miR‐200 expression may contribute to early lung tumorigenesis and that AKT inhibitors may be useful for the treatment of miR‐200‐dependent tumor cell growth. © 2015 IUBMB Life, 67(9):720–725, 2015
Patient Outcomes and Spinal Cord Stimulation: A Retrospective Case Series Evaluating Patient Satisfaction, Pain Scores, and Opioid Requirements
Sanders, Rebecca A., Moeschler, Susan M. , Gazelka, Halena M. , Lamer, Tim J. , Qu, Wenchun , Hoelzer, Bryan C. , Wang, Zhen

Mayo Clinic

Pain Practice | August 27, 2015 | Volume: 16 | Issue: 7 | Pages: 899-904

10.1111/papr.12340 | PMID 26310826 Get It

AbstractIntroductionSpinal cord stimulators (SCS) are used to treat various chronic pain states. Establishing patient outcomes in terms of pain control, opioid medication use, and overall satisfaction is vital in maintaining SCS's role in clinical practice.MethodsAll patients who underwent SCS implantation between January 2001 and December 2011 at a tertiary academic pain medicine center were included if he or she underwent permanent cervical or thoracolumbar dorsal column SCS implantation and age was 18 or greater. For the 199 patients who met inclusion criteria, data were collected retrospectively. Preimplant information included indication for implantation, Numeric Rating Scale (NRS) score, and dose in oral morphine equivalents (OME). Postimplant NRS score was recorded at 6 months and 1 year. OME requirement and patient satisfaction were determined at 1 year postimplantation.ResultsThis data set showed an overall decrease in OME requirements and NRS scores at both 6 months and 1 year. These differences were statistically significant (P < 0.01) compared to preimplantation values. Additionally, 84.27% of patients were satisfied with their implants at 1 year. Patient outcomes were analyzed further in respect to implant indication; groups included failed back surgery syndrome (FBSS), complex regional pain syndrome (CRPS), angina, and other. For all groups, there were statistically significant (P < 0.01) decreases in NRS scores at 6 months and 1 year. In the FBSS and CRPS groups, statistically significant (P < 0.02) decreases in OME usage existed.ConclusionRetrospective review of patients with spinal cord stimulators revealed OME reduction at 1 year for those patients in the FBSS and CRPS groups; patient satisfaction at 1 year and NRS score reduction at 6 months and 1 year were statistically significant for all groups.